secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001420720-26-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio reports IBIO-610 reduces visceral fat 6.7%, total fat 5.2% in obese NHPs; expands into cardiopulmonary
--------------------------------------------------------------------------------

- Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.
- Extended half-life of 33.2 days in NHPs; projected human half-life up to 100 days suggesting twice-yearly dosing.
- Company announces strategic expansion into cardiopulmonary space, targeting PH-HFpEF with myostatin x Activin A bispecific.
- Data consistent with other Activin E pathway approaches; full dataset to be presented at scientific conferences in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/0001420720-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/ibio-20260309x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer